PMID- 7495121
OWN - NLM
STAT- MEDLINE
DCOM- 19960111
LR  - 20100324
IS  - 0090-4295 (Print)
IS  - 0090-4295 (Linking)
VI  - 46
IP  - 5
DP  - 1995 Nov
TI  - Loss of HLA class I expression in prostate cancer: implications for 
      immunotherapy.
PG  - 681-6; discussion 686-7
AB  - OBJECTIVES: There is currently no reliable predictor of the metastatic potential 
      of apparently localized prostate cancer in an individual patient or satisfactory 
      treatment for patients with advanced disease. One of the factors that may 
      influence tumor progression is the cellular arm of the immune response, and 
      central to this is the human leukocyte antigen (HLA) system, which acts to 
      restrict T-cell recognition of potential tumor antigens. It has been reported in 
      some cancers that down regulation of HLA class I expression by the tumor cells is 
      associated with poor prognosis. In this report, HLA class I and II expression 
      have been investigated in both benign and malignant prostate disease, first to 
      define the extent of altered HLA expression and second to assess whether HLA 
      expression may be related to disease progression. METHODS: HLA expression was 
      assessed by immunohistochemistry utilizing a set of monoclonal antibodies that 
      recognize both monomorphic determinants and the commoner HLA class I allelic 
      products. RESULTS: In contrast to the normal HLA class I expression of the benign 
      tissue, complete loss of HLA class I expression occurred in 34% of primary 
      prostate cancers and 80% of lymph node metastases. When individual allelic 
      expression was assessed, the minimum estimate of down regulation was 85% in the 
      primary prostate cancers and 100% of the metastases. CONCLUSIONS: This 
      investigation has demonstrated a higher rate of HLA class I loss than has been 
      reported in other tumors and would suggest that the immune system may have an 
      important role in the progression of prostate cancer, as well as having 
      implications for the design and success of immunotherapy regimens in advanced 
      disease.
FAU - Blades, R A
AU  - Blades RA
AD  - Department of Urology, University Hospital of South Manchester, United Kingdom.
FAU - Keating, P J
AU  - Keating PJ
FAU - McWilliam, L J
AU  - McWilliam LJ
FAU - George, N J
AU  - George NJ
FAU - Stern, P L
AU  - Stern PL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genes, MHC Class I/*genetics
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*genetics/therapy
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - S0090-4295(99)80301-X [pii]
AID - 10.1016/S0090-4295(99)80301-X [doi]
PST - ppublish
SO  - Urology. 1995 Nov;46(5):681-6; discussion 686-7. doi: 
      10.1016/S0090-4295(99)80301-X.